Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Acalabrutinib Combo Induces High Responses in CLL

June 5th 2019

Simultaneous targeting of Bruton’s tyrosine kinase and the CD20 antigen led to overall responses in more than 90% of patients with chronic lymphocytic leukemia, including untreated and relapsed/refractory disease.

Chemo-Free Combo Significantly Improves PFS in Previously Untreated CLL

June 4th 2019

The addition of venetoclax to obinutuzumab reduced the risk for disease worsening or death by 65% compared with obinutuzumab plus chlorambucil in patients with previously untreated chronic lymphocytic leukemia.

Dr. Abedin on the Role of Venetoclax Plus Obinutuzumab in CLL

June 4th 2019

Sameem Abedin, MD, assistant professor, Medical College of Wisconsin, discusses the role of venetoclax plus obinutuzumab in chronic lymphocytic leukemia.

Dr. Barrientos on Remaining Challenges in CLL

May 24th 2019

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses remaining challenges in the treatment of patients with chronic lymphocytic leukemia.

Expert Explains Expanding Post-Ibrutinib Options in CLL

May 24th 2019

Jacqueline C. Barrientos, MD, MS, highlights emerging agents in the post-ibrutinib landscape and overall next steps for advancing the field of CLL.

Dr. Brander on Targeted Agents in CLL

May 18th 2019

Danielle M. Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses targeted agents in chronic lymphocytic leukemia (CLL).

Expanding the Utility of Novel Combination Regimens in CLL

May 17th 2019

Danielle M. Brander, MD, discusses the investigational combination treatments that are bringing patients with chronic lymphocytic leukemia one step closer to well-tolerated, time-limited therapy.

FDA Approves Venetoclax/Obinutuzumab Combo for Frontline CLL

May 15th 2019

The FDA has approved the combination of venetoclax and obinutuzumab for the frontline treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dr. Davids Discusses Ongoing Research With Ibrutinib Plus Venetoclax in CLL

May 15th 2019

Matthew S. Davids, MD, MMSc, associate director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses ongoing research with ibrutinib plus venetoclax in chronic lymphocytic leukemia.

Post-Ibrutinib Treatments Show Promise in CLL

May 8th 2019

Sameem Abedin, MD, discusses the recent encouraging data in chronic lymphocytic leukemia with venetoclax, duvelisib, and acalabrutinib.

Acalabrutinib Improves PFS in Relapsed/Refractory CLL

May 7th 2019

Acalabrutinib improved progression-free survival compared with rituximab plus either idelalisib or bendamustine in previously treated patients with chronic lymphocytic leukemia, according to findings from the phase III ASCEND trial.

Dr. Brander on the Safety and Efficacy of Ibrutinib/Venetoclax in CLL

May 7th 2019

Danielle M. Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses the safety and efficacy of the combination of venetoclax (Venclexta) and ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL).

Dr. Abedin Discusses Key Updates in CLL

May 2nd 2019

Sameem Abedin, MD, assistant professor, Medical College of Wisconsin, discusses key updates in the treatment of patients with chronic lymphocytic leukemia.

Novel Agents Show Enhanced Efficacy Across CLL Subtypes

April 19th 2019

Matthew S. Davids, MD, MMSc, discusses recent shifts in the chronic lymphocytic leukemia paradigm with the use of novel therapies and the need to increase personalized treatment with these agents.

Fee-for-Service Unlikely to Disappear Soon

April 15th 2019

Fee-for-service tends to result in a surplus of care and unnecessary medical expense, but it probably won’t disappear from the landscape soon.

Progress in Relapsed/Refractory CLL Could Pave Way for Upfront Advances

April 3rd 2019

Joseph D. Rosenblatt, MD, discusses how advances made in chronic lymphocytic leukemia are changing the outlook for patients and predicts what can be accomplished in the near future.

Dr. Barrientos Discusses Promising Agents in CLL

April 1st 2019

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses promising agents in the treatment of patients with chronic lymphocytic leukemia.

Experts Dissect 3 Practice-Changing Studies for Newly Diagnosed CLL

April 1st 2019

During an OncLive Peer Exchange®, a panel of CLL experts review findings from studies presented at the 2018 American Society of Hematology meeting in December: iLLUMINATE, Alliance A041202, and ECOG E1912.

Dr. Davids on Frontline Challenges in CLL

March 21st 2019

Matthew S. Davids, MD, MMSc, associate director, CLL Center, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses challenges in the frontline treatment of patients with chronic lymphocytic leukemia.

Dr. Wierda on Novel Therapies in Relapsed/Refractory CLL

March 13th 2019

William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses novel therapies in patients with relapsed/refractory chronic lymphocytic leukemia.